Corbion Secures Key US Patent for Algal-Based Omega-3
Corbion, a global leader in sustainable specialty ingredients for food, announces the award of a new US patent for a liquid suspension of algal biomass enriched with omega-3 DHA. This innovation strengthens the company's competitive position in the market for sustainable nutritional solutions.
The patent covers a liquid suspension of lysed algal cells in oil, designed to offer improved stability and performance in animal feed applications. This innovation leverages Corbion's proprietary algal fermentation platform and is based on a unique structure that allows for sustainable differentiation in the market. The AlgaPrime® DHA LS product embodies this technology on a commercial scale, ensuring a rich DHA profile, ease of handling, and greater flexibility in formulating animal feeds.
Global Patent Coverage and Application
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Corbion now holds patents applicable in the United States, Europe, several Latin American territories, China, Australia, and other markets. Additional territories are under review. The AlgaPrime® DHA LS product is widely used in aquaculture feed, animal nutrition, and pet food. Produced on a large scale through algal fermentation, it is fully traceable and reduces reliance on ocean resources.
In line with earlier guidance, Corbion experienced negative growth in both sales and earnings versus Q1 2025.
Corbion a connu une baisse des ventes et des bénéfices par rapport à l'année précédente.
Risks mentioned
Macroeconomic and geopolitical uncertainty create price and supply-chain challenges.
Negative growth in sales and earnings.
High comparable from Q1 2025 impacting results.
Opportunities identified
Sales in Health & Nutrition expected to strengthen from Q2 onwards.
Cost reduction program to deliver savings as of Q2.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
